David Liew drdavidliew
2 years 9 months ago
Is rituximab still a problem with COVID - esp if our patients have been vaccinated pre-ritux?
Antibody titres better when not getting regular ritux around boosters
Maybe boosters 9mo (or so) gap after ritux helps immunogenicity
@TroldborgAnne et al #ACR23 ABST2511 @RheumNow https://t.co/dE0uC6B9hx
Acute anterior uveitis is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA) affecting up to 50% of patients in some age groups. AAU can have a significant impact on quality of life with risk of permanent visual deficits if not adequately treated.
In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.
The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.
Dr. John Cush RheumNow
2 years 9 months ago
The Lupus APOL1 Story
Dr. Kathryn Dao talks with Dr. Ashira Blazer, Rheumatology Research Foundation Dubois Memorial Lecturer on APOL1 High Risk Genotype in SLE: A Genes in Context Story, at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23
https://t.co/VXxJxk0kbS https://t.co/1n1COXcYA4
Dr. Antoni Chan
2 years 9 months ago
ROMO vs DEN.
Romosozumab was superior to denosumab
(ROMO +7.3±4.5%; p< 0.001) and (DEN +2.3±3.1%; p< 0.001) in raising the spine BMD but not in hip at month 12 in chronic GC users with high fracture risk
Mok C Abst#242 #ACR23 @RheumNow https://t.co/q2OKD6C2Me
Janet Pope
2 years 9 months ago
Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR
David Liew drdavidliew
2 years 9 months ago
Wouldn’t it be great to be able to predict which women with RA would improve during pregnancy, & which would worsen? We’d be able to adjust DMARDs accordingly.
Gene expression signatures might tell us more - one key cluster here was 21x predictive.
#ACR23 ABST2481 @RheumNow https://t.co/OiDV5sUiYC
Md Yuzaiful Md Yusof
2 years 9 months ago
#ACR23 Abstr# 2488 Phase 2 RCT #SLE showed more patients on ABBV-599 HD (elsubrutinib (BTK-i) + UPA (JAK-i)) and UPA monotherapy met primary & secondary endpoints vs PBO at WK48W. No major malignancy/VTE concerns. No added superiority by adding BTK-i vs UPA alone @RheumNow https://t.co/MUN2o75gEE
Meral K. El Ramahi, MD MeralElRamahiMD
2 years 9 months ago
During "Rashes in Rheumatology talk at #ACR23, Dr. Katherine Shaw does not routinely use HCQ for DM skin manifestations.
⭐️Only ~10% of DM patients respond to monotherapy with HCQ but potential increased risk of hypersensitivity, especially in MDA5-DM
➡️Suspect that slight HCQ… https://t.co/aRmFmzuAum
Aurelie Najm
2 years 9 months ago
HCQ and risk of retinopathy 👁️
DoD database HCQ 44000+ females & 10000+ males
Risk retinopathy HR 1.5
Variations according to diagnosis SLE higher risk vs. RA, more so in males HR 2, females HR 1.7
No adjustment on HCQ dose
@RheumNow #ACR23 ABST2452 https://t.co/TtTu6ixb45
Meral K. El Ramahi, MD MeralElRamahiMD
2 years 9 months ago
@md_chawla @RheumNow https://t.co/PVxox5t8ZH
Meral K. El Ramahi, MD MeralElRamahiMD
2 years 9 months ago
@md_chawla @RheumNow https://t.co/qSdT7by1Vh
Bella Mehta bella_mehta
2 years 9 months ago
Erosive hand #OA may be more painful than treated #RA patients. The burden of OA is often not alked about, and this study highlights it! @RheumNow #ACR23 https://t.co/jLbvtMmgE0
